Lung cancer cell lines: Useless artifacts or invaluable tools for medical science?

Lung Cancer

Volumn 68, Issue 3, 2010, Pages 309-318

  Gazdar, Adi F ^a   Gao, Boning ^a   Minna, John D ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Cell lines; Genetic instability; Lung cancer; Oncogenes; Preneoplasia; Tumor suppressor genes

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN; PLACEBO; PROTEIN P53; PROTEIN TYROSINE KINASE INHIBITOR;

APOPTOSIS; BRONCHUS; CANCER CELL CULTURE; CANCER GENETICS; CANCER STEM CELL; CARCINOGENESIS; CELL DIFFERENTIATION; CELL DIVISION; CELL GROWTH; CELL IMMORTALIZATION; CLINICAL TRIAL; DRUG SENSITIVITY; GENE AMPLIFICATION; GENE MUTATION; GENE SILENCING; GENE TRANSLOCATION; GENOMIC INSTABILITY; HUMAN; LUNG ALVEOLUS EPITHELIUM; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MALIGNANT TRANSFORMATION; METASTASIS; ONCOGENE; PRIORITY JOURNAL; RESPIRATORY EPITHELIUM; REVIEW; TUMOR VASCULARIZATION; VIRUS GENE; ANIMAL; CELL TRANSFORMATION; CULTURE TECHNIQUE; LUNG TUMOR; NON SMALL CELL LUNG CANCER; PATHOLOGY; RESPIRATORY TRACT MUCOSA; SMALL CELL CARCINOMA; TRANSLATIONAL RESEARCH; TUMOR CELL LINE;

ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; CELL CULTURE TECHNIQUES; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; GENOMIC INSTABILITY; HUMANS; LUNG NEOPLASMS; RESPIRATORY MUCOSA; TRANSLATIONAL RESEARCH; TRANSLATIONAL MEDICAL RESEARCH;

EID: 77952542786     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2009.12.005     Document Type: Review

References (95)

1. Sun S., Schiller J.H., Gazdar A.F. Lung cancer in never smokers-a different disease. Nat Rev Cancer 2007, 7:778-790.
2. Gazdar A.F., Minna J.D. NCI series of cell lines: an historical perspective. J Cell Biochem 1996, (Suppl 24):1-11.
3. Oie H.K., Russell E.K., Carney D.N., Gazdar A.F. Cell culture methods for the establishment of the NCI series of lung cancer cell lines. J Cell Biochem 1996, (Supplement 24):24-31.
4. Masters J.R. HeLa cells 50 years on: the good, the bad and the ugly. Nat Rev Cancer 2002, 2:315-319.
5. van Staveren W.C., Solis D.Y., Hebrant A., Detours V., Dumont J.E., Maenhaut C. Human cancer cell lines: experimental models for cancer cells in situ? For cancer stem cells?. Biochim Biophys Acta 2009, 1795:92-103.
6. Kao J., Salari K., Bocanegra M., Choi Y.L., Girard L., Gandhi J., et al. Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. PLoS One 2009, 4:e6146.
7. Neve R.M., Chin K., Fridlyand J., Yeh J., Baehner F.L., Fevr T., et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006, 10:515-527.
8. Gazdar A.F., Kurvari V., Virmani A., Gollahon L., Sakaguchi M., Westerfield M., et al. Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer. Int J Cancer 1998, 78:766-774.
9. Gazdar A.F., Carney D.N., Russell E.K., Sims H.L., Baylin S.B., Bunn P.A., et al. Establishment of continuous, clonable cultures of small-cell carcinoma of lung which have amine precursor uptake and decarboxylation cell properties. Cancer Res 1980, 40:3502-3507.
10. Coe B.P., Lockwood W.W., Girard L., Chari R., Macaulay C., Lam S., et al. Differential disruption of cell cycle pathways in small cell and non-small cell lung cancer. Br J Cancer 2006, 94:1927-1935.
11. Sriuranpong V., Borges M.W., Ravi R.K., Arnold D.R., Nelkin B.D., Baylin S.B., et al. Notch signaling induces cell cycle arrest in small cell lung cancer cells. Cancer Res 2001, 61:3200-3205.
12. Watkins D.N., Berman D.M., Burkholder S.G., Wang B., Beachy P.A., Baylin S.B. Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer. Nature 2003, 422:313-317.
13. Futreal P.A. Backseat drivers take the wheel. Cancer Cell 2007, 12:493-494.
14. Stratton M.R., Campbell P.J., Futreal P.A. The cancer genome. Nature 2009, 458:719-724.
15. Wistuba I.I., Behrens C., Milchgrub S., Salahuddin S., Ahmadian M., Virmani A.K., et al. Comparison of features of human breast cancer cell lines and their corresponding tumors. Clin Cancer Res 1998, 4:2931-2938.
16. Wistuba I.I., Bryant D., Behrens C., Milchgrub S., Virmani A.K., Ashfaq R., et al. Comparison of features of human lung cancer cell lines and their corresponding tumors. Clin Cancer Res 1999, 5:991-1000.
17. Kwei K.A., Kim Y.H., Girard L., Kao J., Pacyna-Gengelbach M., Salari K., et al. Genomic profiling identifies TITF1 as a lineage-specific oncogene amplified in lung cancer. Oncogene 2008, 3635-3640.
18. Garnis C., Lockwood W.W., Vucic E., Ge Y., Girard L., Minna J.D., et al. High resolution analysis of non-small cell lung cancer cell lines by whole genome tiling path array CGH. Int J Cancer 2006, 118:1556-1564.
19. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
20. Mitsudomi T., Viallet J., Mulshine J.L., Linnoila R.I., Minna J.D., Gazdar A.F. Mutations of ras genes distinguish a subset of non-small-cell lung cancer cell lines from small-cell lung cancer cell lines. Oncogene 1991, 6:1353-1362.
21. Slebos R.J., Rodenhuis S. The molecular genetics of human lung cancer. Eur Respir J 1989, 2:461-469.
22. Singh A., Greninger P., Rhodes D., Koopman L., Violette S., Bardeesy N., et al. A gene expression signature associated with " K-Ras addiction" reveals regulators of EMT and tumor cell survival. Cancer Cell 2009, 15:489-500.
23. Shigematsu S., Lin L., Takahashi T., Nomura M., Suzuki M., Wistuba I., et al. Clinical and biological features associated with Epidermal Growth Factor Receptor gene mutations in lung cancers. J Natl Cancer Inst 2005, 97:339-346.
24. Gandhi J., Zhang J., Xie Y., Soh J., Shigematsu H., Zhang W., et al. Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines. PLoS One 2009, 4:e4576.
25. Gazdar A.F. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene 2009, 28(Suppl 1):S24-S31.
26. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
27. Weir B.A., Woo M.S., Getz G., Perner S., Ding L., Beroukhim R., et al. Characterizing the cancer genome in lung adenocarcinoma. Nature 2007, 450:893-898.
28. Tanaka H., Yanagisawa K., Shinjo K., Taguchi A., Maeno K., Tomida S., et al. Lineage-specific dependency of lung adenocarcinomas on the lung development regulator TTF-1. Cancer Res 2007, 67:6007-6011.
29. Soh J., Okumura N., Lockwood W.W., Yamamoto H., Shigematsu H., Zhang W., et al. Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells. PLoS One 2009, 4:e4566.
30. Inamura K., Takeuchi K., Togashi Y., Hatano S., Ninomiya H., Motoi N., et al. EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Mod Pathol 2009, 22:508-515.
31. Harbour J.W., Lai S.L., Whang-Peng J., Gazdar A.F., Minna J.D., Kaye F.J. Abnormalities in structure and expression of the human retinoblastoma gene in SCLC. Science 1988, 241:353-357.
32. Takahashi T., Nau M.M., Chiba I., Birrer M.J., Rosenberg R.K., Vinocour M., et al. p53: a frequent target for genetic abnormalities in lung cancer. Science 1989, 246:491-494.
33. Otterson G.A., Kratzke R.A., Coxon A., Kim Y.W., Kaye F.J. Absence of p16INK4 protein is restricted to the subset of lung cancer lines that retains wildtype RB. Oncogene 1994, 9:3375-3378.
34. Virmani A.K., Fong K.M., Kodagoda D., McIntire D., Hung J., Tonk V., et al. Allelotyping demonstrates common and distinct patterns of chromosomal loss in human lung cancer types. Genes Chrom Cancer 1998, 21:308-319.
35. Sanchez-Cespedes M., Parrella P., Esteller M., Nomoto S., Trink B., Engles J.M., et al. Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. Cancer Res 2002, 62:3659-3662.
36. Medina P.P., Romero O.A., Kohno T., Montuenga L.M., Pio R., Yokota J., et al. Frequent BRG1/SMARCA4-inactivating mutations in human lung cancer cell lines. Hum Mutat 2008, 29:617-622.
37. Rodriguez-Nieto S., Sanchez-Cespedes M. BRG1 and LKB1: tales of two tumor suppressor genes on chromosome 19p and lung cancer. Carcinogenesis 2009, 30:547-554.
38. Dammann R., Li C., Yoon J.H., Chin P.L., Bates S., Pfeifer G.P. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet 2000, 25:315-319.
39. Burbee D.G., Forgacs E., Zochbauer-Muller S., Shivakumar L., Fong K., Gao B., et al. Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst 2001, 93:691-699.
40. Whang-Peng J., Kao-Shan C.S., Lee E.C., Bunn P.A., Carney D.N., Gazdar A.F., et al. Specific chromosome defect associated with human small-cell lung cancer; deletion 3p(14-23). Science 1982, 215:181-182.
41. Shames D.S., Minna J.D., Gazdar A.F. DNA methylation in health, disease, and cancer. Curr Mol Med 2007, 7:85-102.
42. Wilson I.M., Davies J.J., Weber M., Brown C.J., Alvarez C.E., MacAulay C., et al. Epigenomics: mapping the methylome. Cell Cycle 2006, 5:155-158.
43. Lin Y., Liu X., Yue P., Benbrook D.M., Berlin K.D., Khuri F.R., et al. Involvement of c-FLIP and survivin down-regulation in flexible heteroarotinoid-induced apoptosis and enhancement of TRAIL-initiated apoptosis in lung cancer cells. Mol Cancer Ther 2008, 7:3556-3565.
44. Lu B., Mu Y., Cao C., Zeng F., Schneider S., Tan J., et al. Survivin as a therapeutic target for radiation sensitization in lung cancer. Cancer Res 2004, 64:2840-2845.
45. Cao C., Mu Y., Hallahan D.E., Lu B. XIAP and survivin as therapeutic targets for radiation sensitization in preclinical models of lung cancer. Oncogene 2004, 23:7047-7052.
46. Shivapurkar N., Toyooka S., Eby M.T., Huang C.X., Sathyanarayana U.G., Cunningham H.T., et al. Differential inactivation of caspase-8 in lung cancers. Cancer Biol Ther 2002, 1:65-69.
47. Shivapurkar N., Reddy J.L., Matta H., Sathyanarayana U.G., Huang C.X., Toyooka S., et al. Loss of expression of death-inducing signaling complex (DISC) components in lung cancer cell lines and the influence of MYC amplification. Oncogene 2002, 55:8510-8514.
48. Kim N.W., Piatyszek M.A., Prowse K.R., Harley C.B., West M.D., Ho P.L., et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994, 266:2011-2015.
49. Norrby K. In vivo models of angiogenesis. J Cell Mol Med 2006, 10:588-612.
50. Wu W., O'Reilly M.S., Langley R.R., Tsan R.Z., Baker C.H., Bekele N., et al. Expression of epidermal growth factor (EGF)/transforming growth factor-alpha by human lung cancer cells determines their response to EGF receptor tyrosine kinase inhibition in the lungs of mice. Mol Cancer Ther 2007, 6:2652-2663.
51. Kenny P.A. Three-dimensional extracellular matrix culture models of EGFR signalling and drug response. Biochem Soc Trans 2007, 35:665-668.
52. Upadhyay S., Liu C., Chatterjee A., Hoque M.O., Kim M.S., Engles J., et al. LKB1/STK11 suppresses cyclooxygenase-2 induction and cellular invasion through PEA3 in lung cancer. Cancer Res 2006, 66:7870-7879.
53. Wang X.Q., Li H., Van Putten V., Winn R.A., Heasley L.E., Nemenoff R.A. Oncogenic K-Ras regulates proliferation and cell junctions in lung epithelial cells through induction of cyclooxygenase-2 and activation of metalloproteinase-9. Mol Biol Cell 2009, 20:791-800.
54. Sy S.M., Fan B., Lee T.W., Mok T.S., Pang E., Yim A., et al. Spectral karyotyping indicates complex rearrangements in lung adenocarcinoma of nonsmokers. Cancer Genet Cytogenet 2004, 153:57-59.
55. Grigorova M., Lyman R.C., Caldas C., Edwards P.A. Chromosome abnormalities in 10 lung cancer cell lines of the NCI-H series analyzed with spectral karyotyping. Cancer Genet Cytogenet 2005, 162:1-9.
56. Ogiwara H., Kohno T., Nakanishi H., Nagayama K., Sato M., Yokota J. Unbalanced translocation, a major chromosome alteration causing loss of heterozygosity in human lung cancer. Oncogene 2008, 27:4788-4797.
57. Luo J., Emanuele M.J., Li D., Creighton C.J., Schlabach M.R., Westbrook T.F., et al. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 2009, 137:835-848.
58. Whitehurst A.W., Bodemann B.O., Cardenas J., Ferguson D., Girard L., Peyton M., et al. Synthetic lethal screen identification of chemosensitizer loci in cancer cells. Nature 2007, 446:815-819.
59. Pao W., Miller V.A., Politi K.A., Riely G.J., Somwar R., Zakowski M.F., et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005, 2:e73.
60. Baggerly KA, Coombes KR. Deriving chemosensitivity from cell lines: forensic bioinformatics and reproducible reasearch in high throuput biology. Ann Appl Statist 2009, in press.
61. Yagui-Beltran A., He B., Jablons D.M. The role of cancer stem cells in neoplasia of the lung: past, present and future. Clin Transl Oncol 2008, 10:719-725.
62. Seo D.C., Sung J.M., Cho H.J., Yi H., Seo K.H., Choi I.S., et al. Gene expression profiling of cancer stem cell in human lung adenocarcinoma A549 cells. Mol Cancer 2007, 6:75.
63. Meng X., Li M., Wang X., Wang Y., Ma D. Both CD133+ and CD133- subpopulations of A549 and H446 cells contain cancer-initiating cells. Cancer Sci 2009, 100:1040-1046.
64. Sullivan F.J., Carmichael J., Glatstein E., Mitchell J.B. Radiation biology of lung cancer. J Cell Biochem Suppl 1996, 24:152-159.
65. Carmichael J., Degraff W.G., Gamson J., Russo D., Gazdar A.F., Levitt M.L., et al. Radiation sensitivity of human lung cancer cell lines. Eur J Cancer Clin Oncol 1989, 25:527-534.
66. Chen D.J., Nirodi C.S. The epidermal growth factor receptor: a role in repair of radiation-induced DNA damage. Clin Cancer Res 2007, 13:6555-6560.
67. Eder M., Scherr M. MicroRNA and lung cancer. N Engl J Med 2005, 352:2446-2448.
68. Weiss G.J., Bemis L.T., Nakajima E., Sugita M., Birks D.K., Robinson W.A., et al. EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines. Ann Oncol 2008, 19:1053-1059.
69. Kumar M.S., Erkeland S.J., Pester R.E., Chen C.Y., Ebert M.S., Sharp P.A., et al. Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proc Natl Acad Sci USA 2008, 105:3903-3908.
70. Yamada H., Yanagisawa K., Tokumaru S., Taguchi A., Nimura Y., Osada H., et al. Detailed characterization of a homozygously deleted region corresponding to a candidate tumor suppressor locus at 21q11-21 in human lung cancer. Genes Chrom Cancer 2008, 47:810-818.
71. Thomas R.K., Baker A.C., Debiasi R.M., Winckler W., Laframboise T., Lin W.M., et al. High-throughput oncogene mutation profiling in human cancer. Nat Genet 2007, 39:347-351.
72. Zhao X., Li C., Paez J.G., Chin K., Janne P.A., Chen T.H., et al. An integrated view of copy number and allelic alterations in the cancer genome using single nucleotide polymorphism arrays. Cancer Res 2004, 64:3060-3071.
73. Henderson L.J., Coe B.P., Lee E.H., Girard L., Gazdar A.F., Minna J.D., et al. Genomic and gene expression profiling of minute alterations of chromosome arm 1p in small-cell lung carcinoma cells. Br J Cancer 2005, 92:1553-1560.
74. Shames D.S., Girard L., Gao B., Sato M., Lewis C.M., Shivapurkar N., et al. A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies. PLoS Med 2006, 3:e486.
75. Lockwood W.W., Chari R., Coe B.P., Girard L., Macaulay C., Lam S., et al. DNA amplification is a ubiquitous mechanism of oncogene activation in lung and other cancers. Oncogene 2008, 27:4615-4624.
76. Ramirez R.D., Sheridan S., Girard L., Sato M., Kim Y., Pollack J., et al. Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins. Cancer Res 2004, 64:9027-9034.
77. Sato M., Vaughan M.B., Girard L., Peyton M., Lee W., Shames D.S., et al. Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells. Cancer Res 2006, 66:2116-2128.
78. Reddel R.R., Salghetti S.E., Willey J.C., Ohnuki Y., Ke Y., Gerwin B.I., et al. Development of tumorigenicity in simian virus 40-immortalized human bronchial epithelial cell lines. Cancer Res 1993, 53:985-991.
79. Viallet J., Liu C., Edmond J., Tsao M.-S. Characterization of human bronchial epithelial cells immortalized by the E6 and E7 genes of human papillomavirus type 16. Exp Cell Res 1994, 212:36-41.
80. Reddel R.R., Ke Y., Gerwin B.I., McMenamin M.G., Lechner J.F., Su R.T., et al. Transformation of human bronchial epithelial cells by infection with SV40 or adenovirus-12 SV40 hybrid virus, or transfection via strontium phosphate coprecipitation with a plasmid containing SV40 early region genes. Cancer Res 1988, 48:1904-1909.
81. Vaughan M.B., Ramirez R.D., Wright W.E., Minna J.D., Shay J.W. A three-dimensional model of differentiation of immortalized human bronchial epithelial cells. Differentiation 2006, 74:141-148.
82. Fulcher M.L., Gabriel S.E., Olsen J.C., Tatreau J.R., Gentzsch M., Livanos E., et al. Novel human bronchial epithelial cell lines for cystic fibrosis research. Am J Physiol Lung Cell Mol Physiol 2009, 296:L82-91.
83. Farwell D.G., Shera K.A., Koop J.I., Bonnet G.A., Matthews C.P., Reuther G.W., et al. Genetic and epigenetic changes in human epithelial cells immortalized by telomerase. Am J Pathol 2000, 156:1537-1547.
84. Sharma S.V., Bell D.W., Settleman J., Haber D.A. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007, 7:169-181.
85. Gazdar A.F. Personalized medicine and inhibition of EGFR signaling in lung cancer. N Engl J Med 2009, 361:1018-1020.
86. Jackman D.M., Yeap B.Y., Sequist L.V., Lindeman N., Holmes A.J., Joshi V.A., et al. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res 2006, 12:3908-3914.
87. Das A.K., Chen B.P., Story M.D., Sato M., Minna J.D., Chen D.J., et al. Somatic mutations in the tyrosine kinase domain of epidermal growth factor receptor (EGFR) abrogate EGFR-mediated radioprotection in non-small cell lung carcinoma. Cancer Res 2007, 67:5267-5274.
88. Das A.K., Sato M., Story M.D., Peyton M., Graves R., Redpath S., et al. Non-small cell lung cancers with kinase domain mutations in the epidermal growth factor receptor are sensitive to ionizing radiation. Cancer Res 2006, 66:9601-9608.
89. Guha U., Chaerkady R., Marimuthu A., Patterson A.S., Kashyap M.K., Harsha H.C., et al. Comparisons of tyrosine phosphorylated proteins in cells expressing lung cancer-specific alleles of EGFR and KRAS. Proc Natl Acad Sci USA 2008, 105:14112-14117.
90. Johnson R.L., Huang W., Jadhav A., Austin C.P., Inglese J., Martinez E.D. A quantitative high-throughput screen identifies potential epigenetic modulators of gene expression. Anal Biochem 2008, 375:237-248.
91. Piao C.Q., Liu L., Zhao Y.L., Balajee A.S., Suzuki M., Hei T.K. Immortalization of human small airway epithelial cells by ectopic expression of telomerase. Carcinogenesis 2005, 26:725-731.
92. Lundberg A.S., Randell S.H., Stewart S.A., Elenbaas B., Hartwell K.A., Brooks M.W., et al. Immortalization and transformation of primary human airway epithelial cells by gene transfer. Oncogene 2002, 21:4577-4586.
93. Schweppe R.E., Klopper J.P., Korch C., Pugazhenthi U., Benezra M., Knauf J.A., et al. DNA profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J Clin Endocrinol Metab 2008, 93:4331-4341.
94. Nardone R.M. Eradication of cross-contaminated cell lines: a call for action. Cell Biol Toxicol 2007, 23:367-372.
95. Ringel M.D. "Thyroid cancer" cell line misidentification: a time for proactive change. J Clin Endocrinol Metab 2008, 93:4226-4227.